SKYRIZI® (risankizumab-rzaa) receives FDA approval as the first and only targeted interleukin-23 (IL_23) to treat moderate to severe active Crohn's disease in adults

Media coverage

• Title	US FDA approves AbbVie's interleukin-23 inhibitor, Skyrizi to treat moderately to severely active Crohn's disease
  Media name/outlet	PharmaBiz
  Country/Territory	India
  Date	21/06/22
  Persons	Marla Dubinsky

• Title	SKYRIZI® (risankizumab-rzaa) receives FDA approval as the first and only targeted interleukin-23 (IL_23) to treat moderate to severe active Crohn's disease in adults
  Media name/outlet	CE Noticias Financieras English
  Country/Territory	United States
  Date	20/06/22
  Persons	Marla Dubinsky